WaveMan
WaveMan · Company
ELAB · Pmgc Holdings Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ELAB Pmgc (ELAB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001840563
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
11
13F, latest reported quarter

What the filings say about ELAB

Activist stakes (13D), 180 days
1 filing
Largest: 7.4% of the class

Pmgc insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PMGC Holdings Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
11 funds bought in last quarter
below 80% of Pharma & Biotech
Revenue
-65.5% year over year
below 83% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 83% of Pharma & Biotech
The situation: each line is one rule over one dataset
Graydon Bensler disclosed a 5%+ stake (7.4%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ELAB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-98.2%12M
-99%-66%-33%+0%2025-102025-122026-022026-042026-062026-082026-10 2026-06-03 · Graydon Bensler filed a 5%+ stake (7.4%)2026-06-03 · GB Capital Ltd. filed a 5%+ stake (7.4%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ELAB: institutional holders (13F)

13F holdings, latest reported quarter
JANE STREET GROUP, LLC
81,501 sh
$98.6K
MORGAN STANLEY
53,000 sh
$64.1K
VANGUARD FIDUCIARY TRUST CO
34,014 sh
$41.2K
GEODE CAPITAL MANAGEMENT, LLC
24,077 sh
$29.1K
CITADEL ADVISORS LLC
20,702 sh
$25.0K

Congress trades in ELAB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Graydon Bensler
Activist 13D · 2026-06-03
7.4%
GB Capital Ltd.
Activist 13D · 2026-06-03
7.4%

ELAB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ELAB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$11.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 11 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ELAB financials

Revenue growth
-65.5%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-523.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-104.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-58.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$590.1Kn/a$1.7M$766.3K
Gross profit$185.3Kn/a$1.1M$447.3K
Net income-$7.7M-$6.2M-$4.3M-$1.8M
EPS (diluted)n/an/a-0.40-0.19
Operating cash flow-$5.9M-$5.5M-$4.6M-$1.6M
Cashn/a$4.0M$3.3Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

ELAB Stock Sonar score 4/7 axes

Find similar shapesCompare

ELAB ranks highest on profitability (36th percentile) and risk and compliance (33rd), and lowest on growth (17th), among Pharma & Biotech peers.

Profitability
36
Inputs
  • Return on equity-104.6% · 32 pct, sector of 545
  • Return on assets-58.7% · 39 pct, sector of 691
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Growth
17
Inputs
  • Revenue growth, YoY-65.5% · 17 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
20
Inputs
  • Funds adding, latest quarter11 · 20 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
33
Inputs
  • Short interest, % of float+3.6% · 65 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+64.9% · 2 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ELAB filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 7.4% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies